Recordati Industria Chimica e Farmaceutica Future Growth

Future criteria checks 3/6

Recordati Industria Chimica e Farmaceutica se prevé un crecimiento anual de los beneficios y los ingresos de 10.1% y 5.7% respectivamente. Se prevé que el BPA sea de grow en 10.6% al año. Se prevé que la rentabilidad de los fondos propios sea de 36.8% en 3 años.

Key information

9.0%

Earnings growth rate

9.4%

EPS growth rate

Pharmaceuticals earnings growth	20.0%
Revenue growth rate	5.5%
Future return on equity	36.6%
Analyst coverage	Good
Last updated	03 Apr 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:RER1 - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,526	535	615	690	5
12/31/2025	2,436	530	543	636	8
12/31/2024	2,299	481	481	552	9
12/31/2023	2,082	389	102	485	N/A
9/30/2023	2,032	375	134	510	N/A
6/30/2023	2,005	389	438	507	N/A
3/31/2023	1,985	340	360	456	N/A
12/31/2022	1,853	312	367	462	N/A
9/30/2022	1,801	331	391	485	N/A
6/30/2022	1,702	330	422	504	N/A
3/31/2022	1,615	393	445	491	N/A
12/31/2021	1,580	386	404	492	N/A
9/30/2021	1,511	377	373	475	N/A
6/30/2021	1,460	365	303	413	N/A
3/31/2021	1,404	334	259	425	N/A
12/31/2020	1,449	355	272	404	N/A
9/30/2020	1,475	389	-112	362	N/A
6/30/2020	1,499	391	-84	388	N/A
3/31/2020	1,528	388	-101	336	N/A
12/31/2019	1,482	369	-125	319	N/A
9/30/2019	1,439	328	210	318	N/A
6/30/2019	1,399	322	202	301	N/A
3/31/2019	1,369	318	249	346	N/A
12/31/2018	1,352	312	273	358	N/A
9/30/2018	1,338	307	270	362	N/A
6/30/2018	1,333	306	210	307	N/A
3/31/2018	1,313	297	-58	277	N/A
12/31/2017	1,288	289	-48	273	N/A
9/30/2017	1,255	275	N/A	244	N/A
6/30/2017	1,217	262	N/A	286	N/A
3/31/2017	1,194	250	N/A	273	N/A
12/31/2016	1,154	237	N/A	255	N/A
9/30/2016	1,126	229	N/A	266	N/A
6/30/2016	1,096	218	N/A	261	N/A
3/31/2016	1,074	212	N/A	258	N/A
12/31/2015	1,048	199	N/A	247	N/A
9/30/2015	1,030	190	N/A	231	N/A
6/30/2015	1,019	181	N/A	217	N/A
3/31/2015	1,003	170	N/A	198	N/A
12/31/2014	987	161	N/A	179	N/A
9/30/2014	982	156	N/A	192	N/A
6/30/2014	972	146	N/A	167	N/A
3/31/2014	957	139	N/A	167	N/A
12/31/2013	942	134	N/A	171	N/A
9/30/2013	910	127	N/A	147	N/A
6/30/2013	886	126	N/A	150	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: RER1(10.1% al año) es superior a la tasa de ahorro (0.6%).

Beneficios frente mercado: RER1Se prevé que los beneficios de la empresa (10.1% al año) crezcan menos que el mercado German (13% al año).

Beneficios de alto crecimiento: RER1Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: RER1Se prevé que los ingresos de la empresa (5.5% al año) crezcan más deprisa que los del mercado German (5.4% al año).

Ingresos de alto crecimiento: RER1Se prevé que los ingresos de la empresa (5.7% al año) crezcan más despacio que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): RER1se prevé que la Rentabilidad de los fondos propios sea alta dentro de 3 años (36.8%)

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Recordati Industria Chimica e Farmaceutica Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Full year 2023 earnings released: EPS: €1.89 (vs €1.52 in FY 2022)

Final dividend increased to €0.63

Full year 2023 earnings released

Recordati Industria Chimica e Farmaceutica S.p.A. to Report First Half, 2024 Results on Jul 30, 2024

Recordati Industria Chimica e Farmaceutica S.p.A. to Report Fiscal Year 2023 Results on Feb 22, 2024

Third quarter 2023 earnings released: EPS: €0.37 (vs €0.44 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.51 (vs €0.27 in 2Q 2022)

Upcoming dividend of €0.60 per share at 2.6% yield

First quarter 2023 earnings released: EPS: €0.60 (vs €0.47 in 1Q 2022)

Full year 2022 earnings released

Recordati Industria Chimica e Farmaceutica S.p.A. to Report First Half, 2023 Results on Jul 28, 2023

Upcoming dividend of €0.55 per share

Third quarter 2022 earnings released: EPS: €0.44 (vs €0.43 in 3Q 2021)

Second quarter 2022 earnings released: EPS: €0.27 (vs €0.57 in 2Q 2021)

Upcoming dividend of €0.57 per share

First quarter 2022 earnings released: EPS: €0.47 (vs €0.44 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of €0.53 per share

Third quarter 2021 earnings released: EPS €0.43 (vs €0.38 in 3Q 2020)

Second quarter 2021 earnings released

Upcoming dividend of €0.55 per share

First quarter 2021 earnings released: EPS €0.44 (vs €0.54 in 1Q 2020)

Full year 2020 earnings released: EPS €1.73 (vs €1.80 in FY 2019)

Full year 2020 earnings released

Revenue misses expectations

New 90-day low: €41.04

New 90-day low: €41.96

New 90-day low: €42.47

Recordati Announces the European Medicines Agency Accepts Marketing Authorization Application Submission by ARS Pharmaceuticals for review of ARS-1

ARS Pharmaceuticals, Inc. Announces Licensing Agreement with Recordati for Commercialization of Neffy

Third quarter 2020 earnings released: EPS €0.38

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

New 90-day high: €48.79

New 90-day low: €43.54

ARS Pharmaceuticals, Inc. and Recordati Announce Exclusive License for the Rights in Europe and Additional Countries for Neffy (Ars-1; Epinephrine Nasal Spray)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies